ASAHI INTECC CO., LTD.

Business Details

The Company's core segment develops, manufactures, and sells minimally invasive treatment products (treatment guidewires and catheters) used in endovascular therapy. Domestic sales are primarily direct, while overseas sales are mainly through distributors, with direct sales operations in the US, France, Germany, and Italy. The segment's mainstay is the cardiovascular field (PCI Guidewire, Penetration Catheter, etc.), and it is expanding product offerings into non-cardiovascular fields such as peripheral, cerebral, and abdominal vascular systems. Products are supplied to 121 countries and regions worldwide, and the segment accounts for approximately 87% of consolidated net sales, making it the Company's flagship segment.

Recent Overview

Sales increased across all domestic and overseas regions, with segment profit margin improving to over 38%.

For the cumulative first three quarters of FY2026 (ending June 2026) (July 2025 to March 2026), Medical Business net sales were ¥94,766 million (up 14.6% year on year), and segment profit was ¥36,132 million (up 31.8% year on year). Domestically, procured peripheral vascular products performed well. Overseas, both cardiovascular products (PCI Guidewire, Penetration Catheter) and non-cardiovascular products (peripheral, abdominal vascular) increased in all regions. By region, China led with ¥28,092 million, followed by Europe with ¥21,346 million and North America with ¥19,181 million. Gross profit margin also rose due to productivity improvements, and segment profit margin improved significantly from 33.1% in the same period of the prior year to 38.1%.

Key Products

Growth Drivers

• Continued expansion of market share across all regions in the cardiovascular field, centered on PCI Guidewire
• Expansion of case volumes in the Chinese market and high growth in cerebral and abdominal vascular products (China sales of ¥28,092 million for the period, up 21.6% year on year)
• Strengthening of direct sales in the non-cardiovascular field (peripheral, cerebral, abdominal vascular) in the US market
• Phased transition to direct sales in Europe (France, Germany, Italy) to improve profitability
• Productivity improvements through an integrated production system at overseas plants in Thailand, Vietnam, and the Philippines
• Advancement of the growth strategy under the medium-term management plan "Building the Future 2030"

Risks

• Foreign exchange risk (a stronger yen reduces the yen-converted value of overseas sales)
• Risk from regulatory and policy changes such as bidding systems in the Chinese market
• Risk of declining gross profit margin due to the impact of US tariffs
• Impairment risk on fixed assets (an impairment loss of ¥9,300 million was recorded in the same period of the prior year)
• Valuation risk for goodwill and intangible assets (changes in the business value of acquired companies)
• Operational risk and BCP response at overseas manufacturing sites (Thailand, Vietnam, Philippines)